News articles about Cleveland BioLabs (NASDAQ:CBLI) have been trending somewhat negative recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of -0.02 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.0577581623479 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of CBLI traded down $0.14 during mid-day trading on Friday, reaching $1.85. The company had a trading volume of 27,828 shares, compared to its average volume of 16,924. Cleveland BioLabs has a twelve month low of $1.85 and a twelve month high of $4.25.

About Cleveland BioLabs

Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.

See Also: Leveraged Buyout (LBO) Explained

Insider Buying and Selling by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.